Dine Brands International Announces 2025 Restaurant Development Plans
13.3.2025 15:00:00 EET | Business Wire | Press release
Dine Brands International – an affiliate of Dine Brands Global, Inc., the parent company of Applebee’s Neighborhood Grill + Bar®, IHOP®, and Fuzzy’sTaco Shop® restaurants – is set to expand its dual-branded Applebee’s and IHOP concept in 2025. This expansion includes entering the Costa Rican market with franchisee BLT UK Holdings Limited, and opening the first non-traditional restaurants in Mexico with franchisees Grupo Shogua and ATH Group.
The dual-branded format, combining Applebee’s and IHOP under one roof, has been a key part of Dine Brands’ international growth strategy. Currently, there are 18 dual-branded locations across seven markets: Mexico, Canada, UAE, Kuwait, Saudi Arabia, Honduras, and Peru. In 2025, the company aims to open 13 additional dual-branded restaurants in new international markets and complete 10 dual conversions, bringing the total number of dual-branded restaurants to 41. Franchisee BLT UK Holdings Limited opened the first dual-branded restaurant in Honduras in 2024 and plans to open a second location this year. They will also be opening the first dual-branded restaurant in Costa Rica this Summer in San Jose.
Building on the success of 2024, where Dine Brands International and its franchisees opened 36 new restaurants and entered new markets like Honduras, the 2025 expansion will focus on both traditional and non-traditional growth opportunities. In addition to franchisee ATH Group opening the first non-traditional dual-branded restaurant at the Parador Pedro Escobedo travel center in Mexico, franchisee Grupo Shogua will also open an IHOP restaurant at Felipe Ángeles International Airport (AIFA) in Mexico City.
“I am incredibly proud of the progress we are making to expand and grow with new and existing franchisees around the world,” said Scott Gladstone, President, International and Corporate Development at Dine Brands Global. “Our expansion plans create opportunities to adapt to local customs, tastes, and traditions, as well as new formats and varying footprints. We are committed to creating compelling and profitable opportunities for franchisees and the company, and new and unique experiences for our guests.”
Dine Brands is seeking qualified Master Developers in selected territories in Mexico (Baja California Sur, Sonora, Sinaloa, Aguascalientes, Zacatecas, Coahuila, Durango, Nayarit, Colima, Hidalgo, Guerrero, Oaxaca), selected territories in Canada, as well as Master Franchisees/Master Developers in selected markets in Europe and Asia, including South Korea, Japan, and Spain. For franchising opportunities, please visit https://franchise.ihop.com/en/applebees-co-branded-franchising.
About Dine Brands Global, Inc.
Based in Pasadena, California, Dine Brands Global, Inc. (NYSE: DIN), through its subsidiaries and franchisees, supports and operates restaurants under the Applebee’s Neighborhood Grill + Bar®, IHOP®, and Fuzzy’s Taco Shop® brands. As of December 31, 2024, these three brands consisted of over 3,500 restaurants across 19 international markets. Dine Brands is one of the largest full-service restaurant companies in the world and in 2022 expanded into the Fast Casual segment. For more information on Dine Brands, visit the Company’s website located at www.dinebrands.com.
BR-INTL
View source version on businesswire.com: https://www.businesswire.com/news/home/20250313616481/en/
Contacts
Media Contact
Heather Mann
Director, Global Communications
Dine Brands Global, Inc.
Heather.mann@dinebrands.com - Susan.Nelson@dinebrands.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom